Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 OCT-1 activity measurement provides a superior imatinib response predictor than screening for single-nucleotide polymorphisms of OCT-1.

× No keyword cloud information.

15 in total

1. Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib.

Authors: Deborah L White; Jerald Radich; Simona Soverini; Verity A Saunders; Amity K Frede; Phuong Dang; Daniela Cilloni; Peter Lin; Lidia Mongay; Richard Woodman; Paul Manley; Cassandra Slader; Dong Wook Kim; Fabrizio Pane; Giovanni Martinelli; Giuseppe Saglio; Timothy P Hughes
Journal: Haematologica Date: 2011-12-29 Impact factor: 9.941

Review 2. Selecting the best frontline treatment in chronic myeloid leukemia.

Authors: Musa Yilmaz; Yasmin Abaza; Elias Jabbour
Journal: Curr Hematol Malig Rep Date: 2015-06 Impact factor: 3.952

Review 3. Interaction of innovative small molecule drugs used for cancer therapy with drug transporters.

Authors: K Mandery; H Glaeser; M F Fromm
Journal: Br J Pharmacol Date: 2012-01 Impact factor: 8.739

Review 4. Evolution of therapies for chronic myelogenous leukemia.

Authors: Fabio P S Santos; Hagop Kantarjian; Alfonso Quintás-Cardama; Jorge Cortes
Journal: Cancer J Date: 2011 Nov-Dec Impact factor: 3.360

Review 5. OCT1 and imatinib transport in CML: is it clinically relevant?

Authors: D B Watkins; T P Hughes; D L White
Journal: Leukemia Date: 2015-07-09 Impact factor: 11.528

Review 6. Role of SLC22A1 polymorphic variants in drug disposition, therapeutic responses, and drug-drug interactions.

Authors: C Arimany-Nardi; H Koepsell; M Pastor-Anglada
Journal: Pharmacogenomics J Date: 2015-11-03 Impact factor: 3.550

Review 7. Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy.

Authors: Mohamed A M Ali
Journal: Mol Diagn Ther Date: 2016-08 Impact factor: 4.074

OCT-1 activity measurement provides a superior imatinib response predictor than screening for single-nucleotide polymorphisms of OCT-1.